Role of Lithium Augmentation in the Management of Major Depressive Disorder

  title={Role of Lithium Augmentation in the Management of Major Depressive Disorder},
  author={Michael Bauer and Mazda Adli and Roland Ricken and Emanuel Severus and Maximilian Pilhatsch},
  journal={CNS Drugs},
The high rate of non-responders to initial treatment with antidepressants requires subsequent treatment strategies such as augmentation of antidepressants. Clinical guidelines recommend lithium augmentation as a first-line treatment strategy for non-responding depressed patients. The objectives of this review were to discuss the current place of lithium augmentation in the management of treatment-resistant depression and to review novel findings concerning lithium’s mechanisms of action. We… 
Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis
The evidence base for lithium in the long-term treatment of bipolar disorders has strengthened and lithium remains the most valuable treatment option in this indication.
Lithium treatment for unipolar major depressive disorder: Systematic review
The findings indicate efficacy of lithium as a treatment for some aspects of major depressive disorder, especially as an add-on to antidepressants and for long-term prophylaxis.
Evidence-based pharmacotherapy of treatment-resistant unipolar depression
  • M. Dold, S. Kasper
  • Psychology, Medicine
    International journal of psychiatry in clinical practice
  • 2017
The most convincing body of evidence exists for the augmentation of antidepressants with second-generation antipsychotic drugs and lithium, and both strategies are consistently advised by treatment guidelines as pharmacological first-line strategy in treatment-resistant depression.
Managing inadequate antidepressant response in depressive illness.
Depression frequently fails to respond to initial treatment and strategies with the strongest support are antidepressant augmentation with lithium or second generation antipsychotics and adding cognitive behavioural treatment.
Lithium treatment in the era of personalized medicine
The antisuicidal effect of lithium during its long‐term administration has been demonstrated and should also be taken into account as the element of personalized medicine for the pharmacological prophylaxis of patients with mood disorders.
Key considerations in the pharmacological management of treatment-resistant depression
This manuscript reviews evidence-based treatment strategies for the clinical management of treatment-resistant depression and suggests robust biomarkers that could one day be integrated into clinical practice has the potential to advance specific treatment targets and ultimately improve treatment and remission outcomes.
Mini-review: Anomalous association between lithium data and lithium use
Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials
Atypical antipsychotic augmentation of antidepressant therapy exhibits greater effect size in patients with a higher degree of treatment resistance, which strengthens the rationale for considering atypical antip Psychiatric augmentation among depressed patients with multiple previous treatment failures in clinical practice.


Lithium’s Emerging Role in the Treatment of Refractory Major Depressive Episodes: Augmentation of Antidepressants
Augmentation of antidepressants with lithium is currently the best-evidenced augmentation therapy in the treatment of depressed patients who do not respond to antidepressants.
Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms.
New data on the efficacy and mechanism of action of lithium augmentation are reviewed, showing an unexpected and marked increase in the ACTH and cortisol response in the combined DEX/CRH test.
Augmentation strategies for treatment-resistant depression
Lithium and triiodothyronin (T3) augmentation of tricyclic agents remains the best studied strategy.
Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.
There is firmevidence for lithium as an effective augmentation strategy but only modest evidence for lithium to accelerate response to antidepressants in patients with depressive disorders.
Predictors of efficacy in lithium augmentation for treatment-resistant depression.
Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial.
Lithium was more effective than phenelzine in elderly patients with treatment-resistant major depressive disorder, while tolerance of both treatments was remarkably good in this group of elderly inpatients with many comorbid medical disorders.
Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study.
Patients in this study were treated with a lower dose of lithium, the duration of conventional antidepressant therapy was longer, and they were less depressed and possibly depressed for a longer period, which suggests that lithium is indeed an effective adjunct in some patients with treatment-resistant depression.
Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants
The data suggest limited usefulness of lithium augmentation for patients refractory to multiple treatments, and more definitive data await the outcome of the NIMH Sequential Treatment Alternatives to Relieve Depression (STAR*D) study.
Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression.
Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression.
Lithium augmentation in the continuation phase of treatment of unipolar major depressive disorder effectively protects patients against a relapse.